Samsung Biologics Secures $668M In New Manufacturing Deals With European Pharma

Samsung Biologics is a leading global contract development and manufacturing organisation (CDMO). Today, the firm announced a series of manufacturing agreements with a European pharmaceutical company. These deals are worth over USD 668 million combined and will continue through December 2031. With these latest contracts, Samsung Biologics' total contract value for the year surpasses USD 4 billion.

The company has strategically responded to evolving client needs by securing several major agreements this year, strengthening its partnerships across the U.S., Asia, and Europe. Samsung Biologics now collaborates with 17 of the top 20 pharmaceutical companies worldwide and extends its contracts to help accelerate the development of innovative therapies.

Additionally, Samsung Biologics plans to expand its service offerings by adding antibody-drug conjugate (ADC) capabilities. A dedicated facility for ADC services is expected to be completed by the end of this year, with services including ADC process development and conjugation, building on the company's expertise in biologics and antibody manufacturing. The company is also preparing to launch Bio Campus II, with Plant 5 scheduled to begin operations in April 2025.

John Rim, President and CEO of Samsung Biologics said, “We are delighted to expand our partnership with the European pharmaceutical company toward our shared commitment to delivering high-quality biopharmaceuticals to patients. As we expand strategic collaboration with clients worldwide, we also make continued investments in our capabilities and manufacturing technologies. Our goal is to provide the highest quality services at every stage and deepen our trusted partnerships.”